期刊文献+

厄贝沙坦对高血压的降压作用及逆转左心室肥厚的疗效观察 被引量:1

Clinical observation of irbesartan for depressurized hypertension and reversal left ventriculus pachynsis
下载PDF
导出
摘要 目的 :观察厄贝沙坦的降压疗效及其逆转左心室肥厚的作用。方法 :高血压患者 5 0例 ,给予口服厄贝沙坦 15 0mg ,每天 1次 ,治疗 6周后观察疗效。对其中 2 1例伴左心室肥厚者给予连续服药半年 ,用彩色多普勒超声心动图观察心脏结构有否改变。结果 :5 0例高血压患者治疗 6周后收缩压和舒张压均较治疗前明显下降 (P <0 .0 1)。合并左心室肥厚的 2 1例患者治疗半年后 ,室间隔厚度 (IVST)、左房内径 (LAD)、左室舒张末期内径 (LVDd) ,均较治疗前显著减小 (P <0 .0 1) ,左室射血分数(LVEF)明显改善。治疗过程中未见明显的不良反应。结论 Objective:To investigate the effects of irbesartan for depressurized hypertension and reversal left ventriculus pachynsis.Methods:Fifty cases of hypertension with application of irbesartan,the results were observe after six weeks.Of twenty one cases with left ventriculus pachynsis,the cardiac structures were observe by chromatic doppler ultrasonic cardiogram after six months of continuative dose.Results:Among all 50 hypertensions patient contractive and diastolic pressure decreased obviously six weeks after treating than that before treating( P <0.01).In 21 patients merge left ventricle thick treats the half a year,interventricular septal thickness(IVST),left atrium directly(LAD),left ventricle diastasis directly(LVDd),significantly reduced than before treating( P <0.01) and the left ventricle ejection fraction(LVEF) obviously improvemed.During treatment there were no any obvious bad reaction.Conclusions:Irbesartan can significant reverse left ventriculus pachynsis of hypertension when depressurizing.
作者 王乃玲
出处 《蚌埠医学院学报》 CAS 2003年第6期503-504,共2页 Journal of Bengbu Medical College
关键词 高血压 厄贝沙坦 左心室肥厚 hypertension irbesartan ventriculus sinister pachynsis
  • 相关文献

参考文献9

二级参考文献22

  • 1张登武,张爱梅.安体舒通的研究进展与临床应用[J].心血管病学进展,1994,15(4):234-237. 被引量:6
  • 2龚兰生,刘力生.血压昼夜变异及其临床意义[J].中华心血管病杂志,1994,22(5):323-324. 被引量:307
  • 3陈修 陈维州 曾贵云.心血管药理学[M](第二版)[M].北京:人民卫生出版社,1998.89.
  • 4Adams MA, Trudeau L. Irbesartan: review of pharmacology and comparative properties[J], Can J Clin Pharmacol,2000,7(1): 22-31.
  • 5Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension[J]. Drugs, 1997,54(6):885-902 .
  • 6Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin Ⅱ receptor antagonist[J]. J Hypertens Suppl,1997, 15(7):S15-20.
  • 7Oparil S. Newly emerging pharmacologic differences in angiotensin Ⅱ receptor blockers[J].Am J Hypertens,2000,13(1 Pt 2): 18S-24S .
  • 8Reeves RA, Lin CS, Kassler TK, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis[J].Hypertension,1998,31(6):1311-6.
  • 9Kassler-Taub-K; Littlejohn-T; Elliott-W . Dose-related efficacy of irbesartan for hypertension: an integrated analysis[J].Hypertension,1998,31(6):1311-6.
  • 10Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin Ⅱ receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension[J].J Hum Hypertens,1998,12(3):203-8.

共引文献163

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部